MG

McNair Group

North America, Georgia, United States, Atlanta

Description

McNair Group is a provider of organisational development and outcomes-based skills with the help of a coaching professionals.

Investor Profile

McNair Group has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Private Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Analytics, Big Data, Energy.

Stage Focus

  • Private Equity (50%)
  • Series C (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Analytics
  • Big Data
  • Energy
  • Oil And Gas
  • Software
  • Wind Energy
  • Biotechnology
  • Diabetes
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does McNair Group frequently co-invest with?

Co-Investments: 1
SM
North America, New Jersey, United States, Saddle River
Co-Investments: 1
Houston Ventures
North America, Texas, United States, Houston
Co-Investments: 1
Deerfield
North America, New York, United States, New York
Co-Investments: 1
Redmile Group
North America, California, United States, San Francisco
Co-Investments: 1

Which angels does McNair Group often collaborate with?

CD
North America, Texas, United States, Houston
Shared Deals: 1
EC
North America, Oklahoma, United States, Oklahoma City
Shared Deals: 1

What are some of recent deals done by McNair Group?

Oseberg

Oklahoma City, Oklahoma, United States

Oseberg leverages oil & gas filings in unimaginable ways.

AnalyticsBig DataEnergyOil and GasSoftwareWind Energy
Private EquityJan 14, 2016
Amount Raised: $10,000,000
Xeris Biopharma

Chicago, Illinois, United States

Xeris Biopharma is a pharmaceutical company that develops therapies for patients in endocrinology, neurology, and gastroenterology.

BiotechnologyDiabetesHealth CarePharmaceuticalTherapeutics
Series CJan 7, 2016
Amount Raised: $41,000,000